Deals

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates
AbbVieBrise Pharmaceuticals

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates

Brise Pharmaceuticals Co. Ltd., a portfolio company of Sherpa Healthcare Partners, announced an update on its exclusive license agreement with AbbVie (NYSE: ABBV), originally entered into in 2024. Under the…

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
I-MAB BiopharmaNASDAQ: IMAB

I-Mab to Become U.S.-Based Biotech, Divesting All China Assets for Up to $80 Million

AbbVieAuto-immune

AbbVie Expands Licensing Agreement for Innovative sCAR-T Platform with Scripps Research

CancerDongcheng Pharmaceutical

Yantai Dongcheng Acquires Full Rights to Alfatide II, Targeting Diagnostic and Therapeutic Applications

BiotechCancer

Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion

Show More